2QG Stock Overview
A biopharmaceutical company, engages in the development of drugs to treat cardiovascular diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Quantum Genomics Société Anonyme Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.068 |
| 52 Week High | €0.13 |
| 52 Week Low | €0.0001 |
| Beta | 0.72 |
| 11 Month Change | 11.29% |
| 3 Month Change | 5.59% |
| 1 Year Change | -25.27% |
| 33 Year Change | -98.48% |
| 5 Year Change | -97.84% |
| Change since IPO | -98.65% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2QG | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | 0.8% | -1.3% |
| 1Y | -25.3% | -17.5% | 7.4% |
Return vs Industry: 2QG underperformed the German Biotechs industry which returned -17.5% over the past year.
Return vs Market: 2QG underperformed the German Market which returned 7.4% over the past year.
Price Volatility
| 2QG volatility | |
|---|---|
| 2QG Average Weekly Movement | 5,994.1% |
| Biotechs Industry Average Movement | 6.4% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 2QG's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 2QG's weekly volatility has increased from 2656% to 5994% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 3 | Mathieu Bigois | www.quantum-genomics.com |
Quantum Genomics Société Anonyme, a biopharmaceutical company, engages in the development of drugs to treat cardiovascular diseases. The company develops its drugs based on brain inhibition mechanism of Aminopeptidase A: BAPAI, a triple-action therapeutic platform primarily to treat high blood pressure and heart failure. It is developing firibastat, a treatment for high blood pressure, and in combination with others anti-hypertensive drugs.
Quantum Genomics Société Anonyme Fundamentals Summary
| 2QG fundamental statistics | |
|---|---|
| Market cap | €5.03m |
| Earnings (TTM) | -€9.40m |
| Revenue (TTM) | €19.00 |
Over9,999x
P/S Ratio-0.5x
P/E RatioIs 2QG overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2QG income statement (TTM) | |
|---|---|
| Revenue | €19.00 |
| Cost of Revenue | €1.43m |
| Gross Profit | -€1.43m |
| Other Expenses | €7.97m |
| Earnings | -€9.40m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.13 |
| Gross Margin | -7,547,689.47% |
| Net Profit Margin | -49,478,810.53% |
| Debt/Equity Ratio | -133.6% |
How did 2QG perform over the long term?
See historical performance and comparison